Amplified EPOR / JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Authors:
- June TakedaJTJune Takeda
- Kenichi YoshidaKYKenichi Yoshida
- Masahiro M. NakagawaMNMasahiro M. Nakagawa
- Yasuhito NannyaYNYasuhito Nannya
- Akinori YodaAYAkinori Yoda
- Ryunosuke SaikiRSRyunosuke Saiki
- Yotaro OchiYOYotaro Ochi
- Lanying ZhaoLZLanying Zhao
- Rurika OkudaRORurika Okuda
- Xingxing QiXQXingxing Qi
- Takuto MoriTMTakuto Mori
- Ayana KonAKAyana Kon
Open Access
- 14 July 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 3 (5) , 410-427
Abstract
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, we analyzed 121 AEL using whole-genome, whole-exome, and/or targeted-capture sequencing, together with transcriptome analysis of 21 AEL samples. Combining publicly available sequencing data, we found a high frequency of gains and amplifications involving EPOR/JAK2 in TP53-mutated cases, particularly those having >80% erythroblasts designated as pure erythroid leukemia (10/13). These cases were frequently accompanied by gains and amplifications of ERG/ETS2 and associated with a very poor prognosis, even compared with other TP53-mutated AEL. In addition to activation of the STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism and often showed high sensitivity to ruxolitinib in vitro and in xenograft models, highlighting a potential role of JAK2 inhibition in therapeutics of AEL. Significance: This study reveals the major role of gains, amplifications, and mutations of EPOR and JAK2 in the pathogenesis of pure erythroleukemia. Their frequent response to ruxolitinib in patient-derived xenograft and cell culture models highlights a possible therapeutic role of JAK2 inhibition for erythroleukemia with EPOR/JAK2-involving lesions. This article is highlighted in the In This Issue feature, p. 369Keywords
All Related Versions
Funding Information
- Japan Agency for Medical Research and Development (19ck0106470h0001)
- Japan Agency for Medical Research and Development (15cm0106056h0005)
- Japan Agency for Medical Research and Development (JP19cm0106501h0004)
- Japan Agency for Medical Research and Development (JP16ck0106073h0003)
- Japan Agency for Medical Research and Development (JP19ck0106250h0003)
- Ministry of Education, Culture, Sports, Science and Technology (hp160219)
- Ministry of Education, Culture, Sports, Science and Technology (hp170227)
- Ministry of Education, Culture, Sports, Science and Technology (hp180198)
- Ministry of Education, Culture, Sports, Science and Technology (hp190158)
- Japan Society for the Promotion of Science (JP15H05909)
- Japan Society for the Promotion of Science (JP26221308)
- Japan Society for the Promotion of Science (JP19H05656)
- Japan Society for the Promotion of Science (22H02817)
- Japan Society for the Promotion of Science (JP19H01053)
This publication has 63 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristicsLeukemia, 2013
- An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing dataNucleic Acids Research, 2013
- Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemiaProceedings of the National Academy of Sciences, 2012
- APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cellsEuropean Journal of Haematology, 2010
- Control-free calling of copy number alterations in deep-sequencing data using GC-content normalizationBioinformatics, 2010
- Cytogenetic study of 75 erythroleukemiasCancer Genetics and Cytogenetics, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietinCell, 1993